Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy

Netherlands Journal of Medicine

Volumn 72, Issue 6, 2014, Pages 299-304

  Eskens, F A L M ^a   Van Erpecum, K J ^b   de Jong, K P ^c   van Delden, O M ^d   Klumpen, H J ^d   Verhoef, C ^a   Jansen, P L M ^d   van den Bosch, M A A J ^b   Mendez Romero A ^a   Verheij, J ^d   Bloemena, E ^e   de Man, R A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Hepatocellular carcinoma (HCC); Surveillance; Treatment

Indexed keywords

SORAFENIB;

CANCER INCIDENCE; CANCER SPECIFIC SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; ECHOGRAPHY; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGICAL MONITORING; FEMALE; LIVER NEOPLASMS; MALE; NETHERLANDS; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; EPIDEMIOLOGICAL MONITORING; FEMALE; GUIDELINES AS TOPIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; NETHERLANDS;

EID: 84904699836     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs A. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380-8.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-42.
4. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188-97.
5. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
6. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
7. de Man R. Richtlijn Hepatocellulair Carcinoom (Versie 5.0). 2013. www.oncoline.nl.
8. van Erpecum K. IKNL-richtlijn hepatocellulair carcinoom. Ned Tijdschr Oncol. 2013;10:161-4.
9. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118:818-24.
10. El-Serag H, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-80.
11. Chen C, Yang H, Yang W, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111-21.
12. Marrero J, Fontana R, Fu S, Conjeevaram H, Su G, Lok A. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42:218-24.
13. Singh S, Singh P, Singh A, Murad M, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology. 2013;144:323-32.
14. Zhang Z, Zheng Z, Shi R, Su Q, Jiang Q, Kip K. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:2347-53.
15. Chen H, Shieh J, Chang C, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606-15.
16. Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology. 2007;46:430-5.
17. Witjes C, Karim-Kos H, Visser O, et al. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. Eur J Gastroenterol Hepatol. 2012;24:450-7.
18. Chang M, You S, Chen C, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348-55.
19. Papatheodoridis G, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348-56.
20. Sung J, Tsoi K, Wong V, Li K, Chan H. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067-77.
21. Lai C, Yuen M. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399-408.
22. Zhang B, Yang B, Tang Z. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22.
23. Lederle F, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156:387-9.
24. Singal A, Volk M, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
25. Witjes C, de Man R, Eskens F, et al. Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study. Ned Tijdschr Geneeskd. 2010;154:A1747.
26. van Meer S, de Man R, Siersema P, van Erpecum K. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol. 2013;19:6744-56.
27. Silva M, Hegab B, Hyde C, Guo B, Buckels J, Mirza D. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592-6.
28. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
29. Lu M, Kuang M, Liang L, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2006;86:801-5.
30. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903-12.
31. Huang G, Lee P, Tsang Y, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg. 2005;242:36-42.
32. Chen M, Li J, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-8.
33. Tiong L, Maddern G. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210-24.
34. Llovet J, Real M, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9.
35. Oliveri R, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011 CD004787.
36. Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs. 2010;21:326-32.
37. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-27.